Thermo Fisher Scientific Inc to Post Q1 2018 Earnings of $2.34 Per Share, Jefferies Group Forecasts (TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) – Investment analysts at Jefferies Group dropped their Q1 2018 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research note issued to investors on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings per share of $2.34 for the quarter, down from their prior estimate of $2.35. Jefferies Group currently has a “Hold” rating and a $195.00 price objective on the stock. Jefferies Group also issued estimates for Thermo Fisher Scientific’s Q3 2018 earnings at $2.61 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter last year, the company posted $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. TRADEMARK VIOLATION WARNING: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/11/14/thermo-fisher-scientific-inc-to-post-q1-2018-earnings-of-2-34-per-share-jefferies-group-forecasts-tmo.html.

Several other equities analysts also recently commented on TMO. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a report on Tuesday, August 1st. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, October 30th. Barclays PLC reiterated an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) began coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $205.71.

Thermo Fisher Scientific (NYSE:TMO) opened at $188.21 on Monday. Thermo Fisher Scientific has a twelve month low of $139.07 and a twelve month high of $201.20. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $74,657.32, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the sale, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. Insiders have sold 22,738 shares of company stock worth $4,021,512 in the last quarter. Corporate insiders own 0.49% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of TMO. BlackRock Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after acquiring an additional 22,165,530 shares during the period. Capital Research Global Investors lifted its holdings in shares of Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after acquiring an additional 3,973,136 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Thermo Fisher Scientific by 2,058.1% during the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after acquiring an additional 2,233,522 shares during the period. Veritas Asset Management LLP lifted its holdings in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after acquiring an additional 1,286,259 shares during the period. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after acquiring an additional 1,194,487 shares during the period. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply